OSH - Drug pricing in focus at Citi 1Life earns another bull at Keybanc and more in today's analyst action

Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s Margaret Kaczor thinks the group of med-tech stocks are attractive buys on the pullback.Despite negative stock reactions, the first quarter updates reaffirm the potential for a post-pandemic recovery coupled with their “intact fundamental growth stories,” wrote Kaczor who has outperform ratings on all three stocks.Strong global demand for Impella heart pump ensured a revenue beat for Abiomed in Q1 2021 while Dexcom fell in the post-market despite better than expected Q1 performance.Failure to contain high drug prices could give rise to M&A hurdles: CitiHamstrung in its efforts to cut the high cost of prescription drugs in the U.S., Congress could instead resort to enacting legislative hurdles for potential deals, Citi says.With over $150B worth of sales at stake as some important drugs face

For further details see:

Drug pricing in focus at Citi, 1Life earns another bull at Keybanc, and more in today’s analyst action